Smith Darren Charlton
Known title: Group Chief Financial OfficerCIK: 0002122447
Smith Darren Charlton's purchase track record
Smith Darren Charlton has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/7/2026 | TLX | $20K | pending | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| TLX | ▲ Buy | Open Market | 2,071 | $20K | 9/7/2026 | View on chart |
| TLX | ▲ Buy | Option Exercise | 1,111 | $0 | 3/29/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Telix doses first US patients with FDA-approved Pixclara
Telix has begun dosing the first US patients with Pixclara, its FDA-approved imaging drug for glioma. The company also announced a partnership with Profound Medical to educate physicians on prostate cancer care and plans to host a Capital Markets Day in Melbourne in November 2026.
Telix doses first US patients with FDA-approved Pixclara. Telix has begun dosing the first US patients with Pixclara, its FDA-approved imaging drug for glioma. The company also announced a partnership with Profound Medical to educate physicians on prostate cancer care and plans to host a Capital Markets Day in Melbourne in November 2026.